Head & Neck

Head & Neck Squamous Cell Carcinoma (SCC):

CIRB #H-37278/NRG #HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) Vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin

CIRB #H-32379/ RTOG #R1216: Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

CIRB # H-39827/ NRG #HN005: Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer (pending)

CIRB # H-41338/ NRG #HN006: Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer (pending IRB approval)

WIRB #H-39961/ Celgene #VTX-2337: A Phase 1b Multicenter Pre-Surgical Study to Evaluate Immune Biomarker Modulation in Response to Motolimod (VTX-2337) In Combination With Nivolumab In Subjects With Resectable Squamous Cell Carcinoma Of The Head And Neck (SCCHN) (pending)

IRB #H-38134/ RTOG Foundation #R3507: A Randomized phase II study of Pembrolizumab (KEYTRUDA®) plus Stereotactic Re-Irradiation versus SBRT alone for Locoregionally recurrent or second primary head and neck Carcinoma

Nasopharyngeal:

CIRB #H-33148/NRG #HN001: Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

Salivary Gland:

IRB #H-35696/RTOG #R1008: A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors